Showing results (41-50 of 61) with videos related to
Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|May 13, 2019
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics servicesCathryn A Moss, Elena Cojocaru, Janet Hanwell, et al.Frontiers in Medicine|November 18, 2021
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource ImplicationsSumeet Hindocha, Des Campbell, Merina Ahmed, et al.Cancer Treatment and Research Communications|February 7, 2021
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit ExperienceAndrea Biondo, Abhijit Pal, Ruth Riisnaes, et al.Journal for Immunotherapy of Cancer|June 8, 2026
First-in-human, phase 1, open-label study of alomfilimab, an anti-ICOS antibody, as a single agent and in combination with anti-PD-L1 in advanced malignanciesAung Naing, Chia-Chi Lin, Manish R Patel, et al.Journal for Immunotherapy of Cancer|March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumabAnna Minchom, Wei Yuan, Mateus Crespo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical TrialReetta Virtakoivu, Jenna H Rannikko, Miro Viitala, et al.The Lancet. Oncology|March 20, 2026
A practical toolkit with recommendations for analysing and visualising patient-reported outcomes in early phase dose-finding oncology trials (OPTIMISE-AR)Emily Alger, Antoine Regnault, Amylou C Dueck, et al.Cell Reports. Medicine|December 6, 2023
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trialJenna H Rannikko, Loic Verlingue, Maria de Miguel, et al.The Lancet. Oncology|August 4, 2023
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyShubham Pant, Martin Schuler, Gopa Iyer, et al.Nature Medicine|June 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trialSusana Banerjee, Matthew G Krebs, Alastair Greystoke, et al.Pageof 7